Editor's note: We at EqualOcean tracked the major funding rounds or industry events that took place in China's healthcare space in September 2022. And the following is a list of deals that we have selected for you, based on a number of criteria, including the funding amount, the financial backers, and the segments in which the startups operate.
Chinese innovative vaccine producer VBioSci (Chinese: 鼎持生物) completed a Series B round of financing on September 26, which was worth hundreds of millions of CNY. The fund was jointly led by 3E Bioventures (Chinese: 本草资本) and Sino-Recl Amation Fund (Chinese: 中垦基金). Yijing Capital (Chinese: 沂景资本), Longqing Capital (Chinese: 龙庆资本), Oriental Fortune Capital (Chinese: 东方富海), Hangzhou Zheke Investment Management (Chinese: 浙科投资) and Suzhou Suxin Venture Capital (Chinese: 苏信创投).
Innovation CRO+ Explorer, ICE-BioSci
ICE BioSci (Chinese: 思益普), a CRO enterprise focusing on drug discovery biology, announced that it had completed a Series B round financing of more than CNY 100 million (USD 13.94 million), led by Jifeng Ventures (Chinese: 济峰资本), with the investment of CICC Qide Fund (Chinese: 中金启德基金), Sichuan Guojing Capital Holding (Chinese: 国经资本), Addor Capital (Chinese: 毅达资本), Longmen Capital (Chinese: 隆门资本) and HIIG Equity Investment Fund Management (Chinese: 杭实股权投资基金管理), as well as the additional investment of existing shareholders Lotus Lake Venture Capital (Chinese: 荷塘创投) and Jolmo (Chinese: 金雨茂物).
AccurDx (Chinese: 艾科达) raised over CNY 100 million in a Series A financing round from Addor Capital (Chinese: 毅达资本) and CITIC Medical Fund (Chinese: 中信医疗基金).
Founded in 2017, AccurDx is an innovative enterprise that focuses on hemostasis and thrombus detection. Its products cover blood clotting test systems, immunity-based intrusion detection systems, specific protein detection systems and reproductive detection systems.
Ruihongdi Pharmaceutical (Chinese: 瑞宏迪医药) planned to raise CNY 497 million (USD 66.84 million) through a capital increase and share expansion on September 23, 2022, of which Hengrui Pharma (Chinese: 恒瑞医药) invested CNY 225 million, Shengdi Private Equity Fund (Chinese: 盛迪基金) invested CNY 152 million and Yingtai Asset Management (Chinese: 迎泰资产) invested CNY 120 million.
The company was previously a subsidiary of Hengrui Pharma, established in 2021. It is mainly engaged in the industrial research, development and clinical application of AAV (adeno-associated virus )-based gene therapy drugs and mRNA-based therapeutics, including front-end screening of AAV gene therapy carriers and mRNA liposome carriers, production process optimization, GMP production, clinical quality control standards and clinical trials.
Koutech Medical Robotics
Koutech Medical Robotics (Chinese: 昂泰微精医疗科技有限公司), an ultra-micro and high-precision surgical robot platform company, has recently completed a new round of financing worth hundreds of millions of CNY in Series A round. Qiming Venture Partners (Chinese: 启明创投) led this fund, followed by Proxima Ventures (Chinese: 比邻星创投), DNE Capital (Chinese: 东久新宜资本), Shanghai Lingang Life Blue Bay Fund (Chinese: 临港蓝湾基金), Winfast Holding (Chinese: 瑞华控股) and Koutech's angel round investor TF Capital (Chinese: 泰福资本). Life Venture (Chinese: 生命资本) served as the exclusive financial advisor.
Jiangsu Xunjie Medical Technology
Tencent invested CNY 291 million to become the second largest shareholder of Xunjie Medical (Chinese: 讯捷医疗), a wholly-owned subsidiary of Yuwell Medical. On the evening of September 19, Yuyue Medical disclosed that it planned to introduce Xiangshan Technology, a strategic investor, by means of the capital increase and share expansion. Xiangshan Technology is 100% owned by Tencent. PrimedicGmbH, a subsidiary of Xunjie Medical, has more than 40 years of medical emergency experience. Its semi-automatic external defibrillator and cardiac defibrillation monitor are well known in the global emergency medical devices market.
Vivolight (Chinese: 微光医疗) completed a Series D financing round worth more than CNY 100 million on September 16, 2022. This funding round was led by Fosun Health Capital (Chinese: 复健资本) and Huajin Capital (Chinese: 华金资本), followed by Casstar (Chinese: 中科创星), Sequoia China (Chinese: 红杉中国)and Hainan Xincheng Kaiyuan Investment (Chinese: 海南新成开元投资有限责任公司). Its product line includes projection infrared vascular imager, ophthalmic optical coherence tomography (OCT) imaging system and endoscopic and cardiovascular OCT systems.
The company was specialized in high-end biomedical consumables, Cellprobio (Chinese: 赛普生物) net over hundreds of millions of CNY in the Series B financing round. The fund was jointly invested by Yuanbio Venture Capital (Chinese: 元生创投) and CICC Qichen Fund (Chinese: 中金启辰) under CICC Capital, followed by Xiamen Venture Capital (Chinese: 厦门创投) and Zhongxin Group (Chinese: 中新集团), and the existing shareholders River Head Capital (Chinese: 阳光融汇资本), Hangzhou Oriental Jiafu Asset Management (Chinese: 东方嘉富), Nantong Jiale Investment Management Centre (Chinese: 嘉乐资本), Oriza Holdings (Chinese: 元禾控股) and Shunrong Capital (Chinese: 顺融资本) continued to increase their holdings.
Common Splendor International Health Industry Group /Aidigong Maternal & Child Health
Common Splendor International Health (Chinese: 同佳健康) has obtained a strategic investment of CNY 200 million from Hillhouse Capital (Chinese: 高瓴资本). Headquartered in Hong Kong, CS Health is an anti-aging service provider. The company changed its name to Aidigong Maternal & Child Health Limited on September 20, 2022.
Worgpharma (Chinese: 百明信康) announced the completion of a Series A financing round of nearly CNY 200 million. This round of financing is led by Junson Capital (Chinese: 佳辰资本) and followed by Kaitai Capital (Chinese: 凯泰资本) and Puhua Capital (Chinese: 普华资本). The company's emphasis is placed on allergen diagnosis and allergen-specific immunotherapy.
Great Bay Bio
Great Bay Bio (Chinese: 大湾生物) received over CNY 100 million in the pre-Series B round, which was led by Taixin Capital (Chinese: 泰欣资本). Great Bay Bio is a biomedicine R&D company with AI-driven platforms covering antibody drug discovery, cell line development (Klone 4.0), cell culture medium development (AlfaMedX), and biological process development.
Structural heart devices R&D firm Turlive (Chinese: 臻亿医疗) has completed hundreds of millions of CNY in the pre-Series B round, led by Daohe Star (Chinese: 道禾长期投资), followed by the existing shareholders like Ancheng Capital (Chinese: 安诚资本), Jianfa Xinxing Venture Capital (Chinese: 建发新兴投资), and Jifeng Ventures (Chinese: 济峰资本).
Leadinno Medical Valley
Neuroregulation medical device R&D company, Leadinno Medical Valley (Chinese: 领创医谷), received more than CNY 100 million in a Series A round of financing. ProX Ventures led the investment (Chinese: 比邻星创投) and the existing shareholder Med-Fine Capital (Chinese: 幂方健康基金), followed by Taiyu Capital (Chinese: 泰煜投资), Meihong Investment (Chinese: 美鸿投资), and the previous investor Cowin Capital (Chinese: 同创伟业).
Palline (Chinese: 上海蓬海涞讯) nets hundreds of millions of CNY in Series A+ round. The investors are Yuanbio Venture Capital (Chinese: 元生创投), Golden Ant Investment (Chinese: 金蚂投资), Yunqi Capital (Chinese: 云启资本) and Bojiang Capital (Chinese: 博将资本). Palline is a hospital management consulting and operation data analysis service provider based in Shanghai.
BoomRay Pharmaceuticals (Chinese: 药明博锐) received nearly CNY 300 million in a Series A round of financing. Sequoia China led the financing (Chinese: 红杉中国), followed by River Head Capital (Chinese: 阳光融汇), Tririver Capital (Chinese: 三江资本), Puhua Capital (Chinese: 普华资本), Tsing Song Capital (Chinese: 清松资本), Life Science Capital (Chinese: 生命园创投) and Shenzhen Jinsheng Equity Investment Management (Chinese: 深圳今晟). The R&D pipeline of BoomRay Pharmaceuticals includes nuclide coupled drugs and neutron capture therapy.